宏盛股份(603090.SH):常州中科累计减持10万股
格隆汇9月12日丨宏盛股份(603090.SH)公布,截止减持计划公告日(2019年2月27日),常州市中科江南股权投资中心(有限合伙)(以下简称“常州中科”)持有公司股份375万股,占公司总股本的3.75%。上述股份全部来源于公司首次公开发行股票前取得的股份;其中375万股于2017年8月31日解除限售。
公司于2019年9月12日收到股东常州中科的《关于公司股份减持结果的告知函》。截至本公告日,常州中科通过上海证券交易所集中竞价交易系统累计减持公司股份10万股,占公司总股本的0.1%。常州中科后续的减持计划,将以后续公告的减持计划为准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.